Lactiga is an award-winning, venture-backed biotherapeutics company committed to restoring mucosal immunity in patients with rare immunodeficiency diseases. We are unlocking the full therapeutic value of IgA antibodies developed from human milk to create the next generation of anti-infectives to fight debilitating pathogens including SARS-CoV-2 and its variants.

Lactiga holds 3 granted patents in support of its LCTG-001 program to prevent life-threatening, respiratory mucosal infections in patients with immunodeficiencies like common variable immune deficiency (CVID) and its NIH-funded program LCTG-002 to develop an airway therapeutic to reduce hospitalizations and infections from COVID-19 and its variants in vulnerable populations.